IPO Year: 2014
Exchange: NASDAQ
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Webcast Access: Event: Altamira Therapeutics Full Year 2023 Financial Results and Business Update CallDate: Wednesday, April 10, 2024Time: 8:30 am EDTWebcast URL
HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it will host an Investor and Business Update Call on Monday, December 11, 2023, 8:30 a.m. ET. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides. Webcast Access: Date: Monday, December 11, 2023Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Webcast URL: https://edge.media-server.com/mmc/p/k7s8zdkg Register for Teleconference:
Covadonga Pañeda, Ph.D., to join leadership team as Chief Development Officer for RNA therapeuticsReceipt of NIH grant to help advance siRNA delivery platform for use in extrahepatic inflammatory disordersHAMILTON, BERMUDA / ACCESSWIRE / January 13, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update on its development activities in RNA therapeutics.Growing the Leadership TeamAs part of its ongoing repositioning around RNA therapeutics, the Company is expanding its leadership team with the appointment of Covadonga Pa
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the pricing of a public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common shares, at a combined
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for Mainland China Extension of Exclusive License and Distribution Agreement to include seven additional countries across East and South East Asia with cumulated population > 630 million Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its partner Nuance Pharma, Shanghai, China ("Nuance") to extend the territory covered by their exclusive license and distribution agreement
Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held virtually and in person on September 9-11, 2024, at Lotte New York Palace Hotel in New York City. Event: H.C. Wainwright Presentation On-Demand Date: September 09, 2024 Time: 7:00am ET Webcast: Link Registration: Link Please note that Company presentation date and time are subject to change.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on Altamira Therapeutics Ltd. (NASDAQ:CYTO). The update note includes detailed information on Altamira Therapeutic's management commentary, recent developments, outlook, and risks. The update note is available here. Highlights from the note include: Announces Significant Enhancement of Immune Checkpoint Inhibitor Therapy Using Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models: Altamira Therapeutics has revealed promising outcomes from a study combining Zbtb46 mRNA, delivered via their
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and Denmark Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its Norwegian partner Pharma Nordic AS ("Pharma Nordic") to extend the territory covered by their exclusive distribution agreement for Bentrio® to Sweden and Denmark. Following the successful launch in Norway earlier this year, Pharma Nordic intends to introduce the Bentrio nasal spray for the prevention and treatment of allergic rhinitis in thes
Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Independent analytical testing of Bentrio for > 230 prohibited substances of WADA list found none of themOutcome further confirms Bentrio's suitability for use by athletes in protection against airborne allergens or other particles Altamira Medica Ltd. ("Altamira" or the "Company"), an associate company of Altamira Therapeutics Ltd. (NASDAQ:CYTO), today announced that its preservative-free, drug-free Bentrio® nasal spray for allergic rhinitis was tested successfully for the absence of more than 230 prohibited substances listed by the World Anti-Doping Agency (WADA). This finding further confirms Bentrio's suitability for athletes who mu
Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology results in significant reduction in tumor growth (p<0.0001)Combination of nanoparticles with immune checkpoint inhibitor (anti-PD1) shows even more pronounced improvement, synergistic control of tumor growth with long-term complete remission of tumor in many casesCombination therapy may help to render more solid tumor patients responsive to anti-PD1 therapies (immune checkpoint inhibitors) Results published in Nature Immunology, one of the world's top immunology journals Altamira Therapeutics Ltd. ("Altamira" or the "Company"
Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysmAltamira's SemaPhore™ nanoparticles delivering SOD2 mRNA successfully to mitochondria in aorta wall Positive outcomes suggest potential use of treatment in management of small abdominal aortic aneurysm and prevention of ruptures Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the preprint publication of a study demonstrating effecti
Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- Independent review discusses evidence supporting the use of betahistine to alleviate residual dizziness following physical repositioning procedures in benign paroxysmal positional vertigo (BPPV) patients Betahistine is marketed world-wide, except in the US, and considered standard of care treatment for dizziness / vertigo AM-125 is a nasal spray formulation of betahistine currently being developed by Altamira to overcome low bioavailability of oral formulation and make treatment option also available to US patients Altamira intends to partner or divest AM-125 as part of legacy assets in strategic pivot to RNA delivery tec
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticlesPursuing partnering opportunities with AM-125 legacy asset in vertigo and / or potential other CNS indicationsStreamlining corporate structure; switch in financial reporting from Swiss Francs to US Dollars HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update related to its RNA delivery platform, partnering of its legacy assets, corporate structuring and fin
F-1/A - Altamira Therapeutics Ltd. (0001601936) (Filer)
F-1/A - Altamira Therapeutics Ltd. (0001601936) (Filer)
F-1 - Altamira Therapeutics Ltd. (0001601936) (Filer)
EFFECT - Altamira Therapeutics Ltd. (0001601936) (Filer)
POS AM - Altamira Therapeutics Ltd. (0001601936) (Filer)
20-F/A - Altamira Therapeutics Ltd. (0001601936) (Filer)
6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)
20-F/A - Altamira Therapeutics Ltd. (0001601936) (Filer)
EFFECT - Altamira Therapeutics Ltd. (0001601936) (Filer)
424B4 - Altamira Therapeutics Ltd. (0001601936) (Filer)
Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysmAltamira's SemaPhore™ nanoparticles delivering SOD2 mRNA successfully to mitochondria in aorta wallPositive outcomes suggest potential use of treatment in management of small abdominal aortic aneurysm and prevention of ruptures
Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 118.4% to $1.07 during Thursday's regular session. The market value of their outstanding shares is at $25.5 million. Renovaro (NASDAQ:RENB) stock rose 46.79% to $1.38. The company's market cap stands at $203.5 million. Altamira Therapeutics (NASDAQ:CYTO) shares increased by 29.37% to $1.85. The company's market cap stands at $4.1 million. Purple Biotech (NASDAQ:PPBT) stock rose 23.44% to $0.84. The company's market cap stands at $21.9 million. As per the press release, Q1 earnings came out 2 days ago. P3 Health Partners (NASDAQ:PIII) stock increased by 23.04% to $0.62. The market value of their outstanding shares is at $73.8 millio
Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social media channels of the allergology journal, "Allergy." The Details: Altamira's NASAR trial enrolled 100 patients who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray. The study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS), as well as its secondary efficacy endpoints. “We are delighted to see the great results from the NASAR trial shared by Allerg
Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journalStudy met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013)Corroborated by statistically significant improvement in health-related quality of life and reduced need for relief medicationStudy outcomes support plans for further international expansion
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. The company's market cap stands at $10.5 million. NKGen Biotech (NASDAQ:NKGN) shares moved upwards by 32.0% to $1.46. The company's market cap stands at $33.2 million. The company's, Q4 earnings came out 4 days ago. T2 Biosystems (NASDAQ:TTOO) shares moved upwards by 18.91% to $3.52. The company's market cap stands at $30.9 million. CNS Pharma (NASDAQ:CNSP) shares increased by 18.26% to $0.24. The company's market cap stands at $2.5 million. Altamira Therapeutics (NASDAQ:CYTO) stock moved upwards by 17.39% to $1.66. The market value of their outstanding shares is at $3.7 million. D
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
SC 13D/A - Altamira Therapeutics Ltd. (0001601936) (Subject)
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new applicationsPartnering of legacy assets underway as Company transitions to focused RNA delivery technology providerAchieved 85% reduction in net loss to CHF 3.9 million and eliminated financial debtFinished year with shareholders' equity of CHF 6.5 million, improved by CHF 14.8 million HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond th
Management will host an investor conference call today, May 16th, at 8 a.m. EasternCompany is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release; expects first research collaborations with biopharmaceutical companies in 2023Filed IND submission with FDA for AM-125 in acute vestibular syndrome‘Showcase' RNA development programs AM-401 and AM-411 progressing in KRAS-driven cancers and rheumatoid arthritis, targeting INDs in 2024Divestiture or partnering of legacy assets remains a key strategic focusTop-line data from full NASAR trial with Bentrio in seasonal allergic rhinitis expected in the second quarterHAMILTON, BERMUDA / ACCESSWIRE / M
Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern.Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliverEstablished new business unit, OTC Consumer Health, to support global commercialization of Bentrio nasal spray and successfully established distribution partners covering more than 20 countries so far.Reported completion of enrollment into Bentrio™ house dust mite clinical trial with expected top-line results planned for 2Q-22, and initiation of "COVAMID" clinical trial in acute COVID-19.Completed patient enrollment in Part B of Phase 2 ‘TRAVERS' clinical trial evaluating AM-125 in acute vertigo; expec
HAMILTON, BERMUDA / ACCESSWIRE / April 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it will hold an investor call on Tuesday, April 12, 2022, 8:00 a.m. ET to discuss its full-year 2021 earnings. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides.Date: Wednesday, April 12, 2022 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time)Webcast URL: https://www.webcaster4.com/Webcast/Page/2797/45151Toll-free dial-in number: 877-545-0320International dial-in number: 973-528-0002Participant Access Code: 786152Participants will be greeted b
Building Bentrio™ brand and expanding in European markets510(k) premarket notification for allergy indication submitted to the U.S. Food and Drug Administration ("FDA")Distributors signed up for two key South East Asian countries, highlighting international expansion potentialHAMILTON, BERMUDA / ACCESSWIRE / September 27, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens.Bentrio™ was launched first in Germany under CE mark in late Ju
HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that it will provide a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens, through a live conference call and webcast on Monday, September 27, 2021, at 8:00 AM Eastern Time.To participate telephonically, please dial (888) 506-0062 (U.S.) or (973) 528-0011 (international), conference code 590321. A live, listen-only webcast of the conference call, which will include accompanying slides, can